Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desvenlafaxine vs duloxetine in major depressive disorder
CTR20220328Phase 3Completed
- Sponsor
- Yangtze River Pharmaceutical Group
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of desvenlafaxine in major depressive disorder (MDD), sponsored by Yangtze River Pharmaceutical Group. Started Feb 2022; status: completed.
02
Drugs
desvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20220328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220328.